Stay updated on Lenalidomide Nivolumab Combo in Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide Nivolumab Combo in Relapsed Myeloma Clinical Trial page.

Latest updates to the Lenalidomide Nivolumab Combo in Relapsed Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 added; the government funding lapse notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA government funding notice about site operation status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded Show glossary and updated metadata: Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check64 days agoChange DetectedAdded a dedicated Locations section and explicitly listed Ohio as a study site; removed the older Ohio Locations item and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check93 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.1 on the ClinicalTrials.gov page for NCT03333746. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Lenalidomide Nivolumab Combo in Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide Nivolumab Combo in Relapsed Myeloma Clinical Trial page.